The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia
✍ Scribed by Bernard C. Camins; Jonas Marschall; Shannon R. De Vader; Dawn E. Maker; Matthew W. Hoffman; Victoria J. Fraser
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 157 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1553-5592
- DOI
- 10.1002/jhm.877
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND:
There are limited data on fluoroquinolone resistance and its impact on mortality in cases of Escherichia coli bloodstream infection (BSI).
OBJECTIVE:
To determine risk factors for in‐hospital mortality among patients with E coli BSIs.
DESIGN:
A retrospective case‐control study.
SETTING:
A 1250‐bed tertiary academic medical center.
PATIENTS:
Patients with fluoroquinolone‐resistant E coli BSI from January 1, 2000 through December 31, 2005 with 1:1 matched control patients with fluoroquinolone‐sensitive E coli BSI.
INDEPENDENT OUTCOME:
In‐hospital mortality.
RESULTS:
A total of 93 cases and 93 control patients were included. Compared with control patients, cases were more likely to be admitted from a long‐term care facility (35% vs. 9%; P < .001) and to have a hospital‐acquired bacteremia (54% vs. 33%; P = .008). Crude mortality was 26% for cases and 8% for controls (P = .002). On univariate analysis, predictors for in‐hospital mortality included female gender, admission from a long‐term care facility, APACHE II score >10, Charlson comorbidity score >4, cardiac dysfunction, cirrhosis, renal dysfunction, treatment with corticosteroids, and a fluoroquinolone‐resistant E coli bacteremia. On multivariate analysis, independent risk factors for in‐hospital mortality were cirrhosis (adjusted odds ratio [aOR], 7.2; confidence interval [CI], 1.7–29.8; P = .007), cardiac dysfunction (aOR, 3.9; CI, 1.6–9.4; P = .003), and infection with a fluoroquinolone‐resistant E coli isolate (aOR, 3.9; CI, 1.5–10.2; P = .005).
CONCLUSIONS:
After controlling for severity of illness and multiple comorbidities only fluoroquinolone resistance, cirrhosis, and cardiac dysfunction independently predicted mortality in patients with E coli bacteremia. Journal of Hospital Medicine 2011;6:344–349. © 2011 Society of Hospital Medicine
📜 SIMILAR VOLUMES
## Abstract ## Introduction Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein–Barr virus (EBV), which can be found in a latent pattern in Reed‐Sternberg (RS) cells. However, the impact of the presence of EBV in RS cells and its prognosis are still controversial. We ana